Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals (RIGL) Surpasses Q4 Earnings and Revenue Estimates
Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.80 per share, beating the Zacks Consensus Estimate of $0.55 per share. This compares to break-even earnings per share a year ago.
Should You Add RIGL Stock to Your Portfolio Pre-Q4 Earnings?
Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. Irrespective of how the company fares in Q4, we recommend investors to add the stock to their portfolio.
RIGL Stock Surges 41.4% in a Year: Time to Buy or Sell?
Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. We believe there is more room for growth.
Does Rigel (RIGL) Have the Potential to Rally 40.88% as Wall Street Analysts Expect?
The mean of analysts' price targets for Rigel (RIGL) points to a 40.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Predict a 75.79% Upside in Rigel (RIGL): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 75.8% in Rigel (RIGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Rigel (RIGL) Upgraded to Buy: Here's Why
Rigel (RIGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents
Rigel Pharmaceuticals has shown significant growth, particularly from the acquisition of pralsetinib, leading to a 46% improvement in stock valuation since April. Rigel's pipeline includes three approved drugs and promising candidates like R289 and ocadusertib, with notable advancements in clinical trials and Fast Track designation. Financially, RIGL has turned profitable with a $12.4 million net income in the latest quarter, but high debt and potential cash flow challenges loom.
How Much Upside is Left in Rigel (RIGL)? Wall Street Analysts Think 28.28%
The average of price targets set by Wall Street analysts indicates a potential upside of 28.3% in Rigel (RIGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2024 Earnings Call Transcript
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2024 Earnings Call Transcript
Rigel Pharmaceuticals (RIGL) Q3 Earnings and Revenues Top Estimates
Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.30 per share a year ago.
Rigel Pharmaceuticals: Looking For More Growth
Rigel Pharmaceuticals' strategic acquisitions of GAVRETO and REZLIDHIA, along with strong TAVALISSE sales, position the company for significant growth and potential profitability. Despite historical negative EPS, Rigel has shown upward revenue trends, with recent earnings revealing a 37.03% year-over-year revenue increase and a reduced net loss. Growth opportunities include expanding product labels, advancing the R289 program, and leveraging partnerships, particularly in the growing hematology and oncology markets.
Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships
Rigel Pharmaceuticals has surged 50.1% since my previous article, driven by successful execution, innovative portfolio, strategic partnerships, and pipeline progress. RIGL's FDA-approved drugs, Tavalisse, Rezlidhia, and Gavreto, are key revenue drivers. They have experienced significant sales growth and promise future contributions, particularly from Gavreto. The company's international collaborations and ongoing clinical trials, especially for olutasidenib, indicate potential for new revenue streams and competitive IP in hematology and oncology.
